European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

PARIS (Reuters) – The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *